echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > You can lose up to 24kg!

    You can lose up to 24kg!

    • Last Update: 2022-05-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Eli Lilly and Company announced today that tirzepatide, an investigational dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, is being used in the treatment of obesity.


    The subgroup receiving the highest dose of tirzepatide lost an average of 22.


    The company's GIP/GLP-1 receptor dual agonist, tirzepatide, can activate both GLP-1 receptor and GIP receptor-mediated signaling pathways, and may reduce body weight through a variety of mechanisms, including reducing appetite and increasing energy expenditure , as well as improving the function of beta cells that secrete insulin,


    GIP/GLP-1 receptor dual agonist tirzepatide can simultaneously activate GLP-1 receptor and GIP receptor-mediated signaling pathways, and may reduce body weight through various mechanisms, including reducing appetite, increasing energy expenditure, and improving Insulin-secreting beta cell function, etc.


    ▲ Potential mechanism of action of Tirzepatide (Image source: Eli Lilly's official website)

    ▲ Potential mechanism of action of Tirzepatide (Image source: Eli Lilly's official website)

    In this randomized, double-blind, placebo-controlled Phase 3 trial called SURMOUNT-1, people with obesity (without type 2 diabetes), or those with hypertension, dyslipidemia, obstructive sleep apnea or The overweight population with at least one comorbidity of cardiovascular disease received either placebo or tirzepatide (in doses of 5 mg, 10 mg, or 15 mg)


    Trial results showed that tirzepatide met the co-primary endpoint of the trial, with a mean weight loss of 16.


    Mean weight loss was 16.


    ▲Tirzepatide significantly reduces the weight of obese individuals (Image source: Eli Lilly's official website)

    ▲Tirzepatide significantly reduces the weight of obese individuals (Image source: Eli Lilly's official website)

    In addition, 89% (5 mg group) and 96% (10 mg and 15 mg group) of the groups receiving tirzepatide achieved at least a 5% weight loss, respectively, compared with 28% in the control group


    89% (5 mg group) and 96% (10 mg and 15 mg group) achieved at least a 5% weight loss compared to 28% in the control group

    ▲Tirzepatide allows more obese individuals to achieve weight loss of more than 5% or 20% (Image source: Eli Lilly’s official website)

    ▲Tirzepatide allows more obese individuals to achieve weight loss of more than 5% or 20% (Image source: Eli Lilly’s official website)

    In terms of safety and tolerability, the profile of tirzepatide is similar to other incretin-based weight loss therapies


    "Tirzepatide is the first investigational drug to reduce average body weight by more than 20% in a Phase 3 clinical trial, and these results reinforce our confidence in its potential to help people with obesity,


    Eli Lilly is currently testing tirzepatide in various other phase 3 clinical trials in different types of obesity, with results expected next year


    ▲The clinical development plan of Tirzepatide (Image source: Eli Lilly's official website)

    ▲The clinical development plan of Tirzepatide (Image source: Eli Lilly's official website)

    Historically, most diet pills can only reduce body weight by 5-10%, and there are many safety hazards


    Related reading: Safely lose 15% of your body weight! What is the next breakthrough direction for weight loss therapy?

    References:

    References:

    [1] Lilly's tirzepatide delivered up to 22.


    [1] Lilly's tirzepatide delivered up to 22.


    [2] Lilly Q1 2022 Earnings Call.
    Retrieved April 28, 2022, from https://investor.
    lilly.
    com/static-files/4564bcc0-f719-47d4-a40e-989b1befcaf6
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.